#36氪 #Release #Build #digital #platform #oncology #doctorpatient #services #Good #Doctor #Hui #received #million #yuan #Series #financing
36氪 learned that Liangyihui, an innovative digital medical platform in the oncology field, has completed a series C financing of more than 100 million yuan. This round of financing is led by Qiming Venture Capital, with Detong Capital, old shareholder Danlu Capital, Wang Zhiqi Family Office, Yuanju Capital and old shareholders aggregate capital to follow up the investment, and Haoyue Capital acted as the exclusive financial advisor for this round of financing.
Liangyihui was established in 2015, and 36Kr had detailed reports on it. In order to deal with the current status of information asymmetry in the field of cancer diagnosis and treatment, it built an anti-cancer academic platform, and cut into the content to provide oncologists with comprehensive learning And IP platforms, and carry out popular science for cancer patients and the general public, to solve the pain points of high treatment costs and information asymmetry for cancer patients, and the most complete marketing plan for pharmaceutical companies.It is reported that currentlyActive inGood doctorThere are nearly 200,000 oncologists and nearly 300,000 cancer patients on the Internet.
According to official information, Liangyihui is divided into five product sections: tumor information, sharing the latest developments in the tumor field, disseminating correct tumor prevention concepts; oncologists, service doctors, oncologist knowledge, information, questions and answers, tool APP; patient guides , To provide oncology patients with popular science information and guidelines for seeking medical advice; global consultation centers, where tumor cases often require transnational consultation, and provide remote consultation platforms for domestic and foreign experts; hematological tumor information, more new drugs will be applied to non-solid tumors first, The frontier academic progress is relatively rich.
Enterprise business model summary
Mr. Wang Jue, the founder of Liangyihui, said that tumor is the most important disease threatening public health at present, and it is also the hottest and most promising subject for new drug research and development. Liangyihui aims to be precise by connecting pharmaceutical companies, doctors, hospitals and patients. Match the needs and supplies of all parties in the process of cancer drug treatment, and ultimately allow cancer patients to receive complete diagnosis and treatment and timely use of good drugs.
It is reported that since the epidemic, liangyihui has organized thousands of free consultations for patients and has successfully benefited tens of thousands of patients. During the epidemic, oncologists and patients were linked through online platforms.In the future, Liangyihui will be based on the application scenarios of digital oncology medicine, meet the needs of oncology doctors and patients to seek medical advice, and cooperate with its own Internet hospital to develop into an innovative oncology for pharmaceutical companies, doctors, hospitals and patients driven by technology and data. Medical digital service platform.
For many years, Liangyihui has adhered to and focused on building a professional vertical platform for oncology, bringing together professional participants in all fields, committed to creating the most comprehensive learning and IP platform for oncologists, and providing patients with the most accessible medical services , The most complete marketing plan for pharmaceutical companies.
Mr. Hu Xubo, Partner of Qiming Venture CapitalMeans,
The field of oncology has always been a hot spot for medical innovation and our investment focus; on the other hand, the online and digitalization of medical services is also a long-term trend. After years of accumulation, Liangyihui has grown into a leading digital platform for oncology doctor-patient services in China, and has been recognized by doctors, patients and medicines.
Mr. Xu Qian, a partner of Detong Capital, said,
After 4 years of continuous observation, Liangyihui’s business model has been verified and it has grown into the largest digital medical platform in the vertical field of oncology in China; innovative oncology drugs are the hottest track in the innovative drug industry. On the market, the market demand for the digital medical platform of tumor drugs is urgent and the growth prospect is broad.
Ms. Lu Qinchao, founding and executive partner of Danlu Capital, said,
Liangyihui has always been rooted in the vertical segmentation of oncology. Its continuous provision of value for oncologists has been recognized by the market and customers, and it has also established extremely high barriers to competition. The industry potential of digital marketing is also obvious to all.